Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study


No effective medical therapy is available for patients with primary sclerosing cholangitis (PSC). We evaluated the safety and estimated the efficacy of silymarin in patients with PSC in a pilot study. Thirty patients with PSC were enrolled. Silymarin, 140 mg orally three times daily, was given for 1 year. A statistically significant improvement in serum… (More)
DOI: 10.1007/s10620-007-0052-6


1 Figure or Table

Slides referencing similar topics